(S) -2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Purity>98.0% (GC) ee>99.0% Paritaprevir Intermediate Factory
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Dzina la Chemical | (S) -2-(Boc-Amino)non-8-Enoic Acid |
Mawu ofanana ndi mawu | (S) -2-(tert-Butoxycarbonylamino)non-8-Enoic Acid;(S) -2-(Boc-Amino) -8-Nonenoic Acid;(2S) -2 - [(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Acid;(2S)-2-{[(tert-Butoxy)carbonyl]amino}non-8-Enoic Acid |
Nambala ya CAS | 300831-21-4 |
Nambala ya CAT | Mtengo wa RF-CC347 |
Stock Status | Zilipo |
Molecular Formula | C14H25NO4 |
Kulemera kwa Maselo | 271.35 |
Kuchulukana | 1.035±0.06 g/cm3 |
Mtundu | Ruifu Chemical |
Kanthu | Zofotokozera |
Maonekedwe | Brown Liquid |
Kuyera / Kusanthula Njira | >98.0% (GC) |
ee | > 99.0% |
Test Standard | Enterprise Standard |
Kugwiritsa ntchito | Pakati pa Paritaprevir (CAS: 1216941-48-8) |
Phukusi: Botolo la fluorinated, 25kg / Drum, kapena malinga ndi zomwe kasitomala amafuna
Mkhalidwe Wosungira:Sungani muzitsulo zosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala ndi chinyezi
(S) -2- (Boc-Amino) non-8-Enoic Acid (CAS: 300831-21-4) angagwiritsidwe ntchito ngati wapakatikati mu kaphatikizidwe wa Paritaprevir (CAS: 1216941-48-8) ndi ofanana analogi.Paritaprevir ndi m'badwo wachiwiri wa NS3/4A protease inhibitor, ndi gawo la mankhwala ophatikiza pakamwa, opanda interferon-free hepatitis C virus opangidwa ndi Enanta Pharmaceuticals ndi AbbVie.Pirita ya Paritaprevir, Ombitasvir ndi Ritonavir ya Paritaprevir, Ombitasvir ndi Ritonavir yotengedwa pamodzi ndi Dasabuvir inavomerezedwa kuti azichiza matenda aakulu a HCV genotype 1 ku USA ndi EU m'chaka cha 2014, ndipo anavomerezedwanso kuti azichiza matenda a genotype 4 aakulu a HCV opanda cirrhosis ndi US. FDA mu 2015.